Immunocore (IMCR) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunocore (IMCR) has outperformed Stoke Therapeutics (STOK) over the past year, losing 14.4% versus a loss of 21.5%. Over five years, STOK leads with a +1.8% price change compared with -23.4% for IMCR. Stoke Therapeutics is the larger company by market cap ($1.55 billion vs $1.50 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | STOK |
|---|---|---|
| Share price | $29.09 | $23.95 |
| Market cap | $1.50B | $1.55B |
| 1-day change | -1.09% | -1.40% |
| YTD return | -16.19% | -24.54% |
| 1-year return | -14.42% | -21.48% |
| 5-year return | -23.45% | +1.83% |
| EPS (TTM) | $-0.36 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $40.22 |
| 52-week low | $27.56 | $20.32 |
| Distance from 52-week high | -28.55% | -40.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.64% | +93.99% |
| Average volume | 443.48K | 855.13K |
| Shares outstanding | 51.50M | 64.53M |
| Employees | 524 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
IMCR vs STOK FAQ
Which is bigger, Immunocore or Stoke Therapeutics?
Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.55B compared with $1.50B for Immunocore (IMCR).
Which stock has performed better over the past year, IMCR or STOK?
IMCR returned -14.42% over the past 12 months, compared with -21.48% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Stoke Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Immunocore and Biotechnology: Pharmaceutical Preparations for Stoke Therapeutics.